Maze Therapeutics (NASDAQ:MAZE) Earns Buy Rating from Analysts at Guggenheim

Stock analysts at Guggenheim assumed coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $19.00 price target on the stock. Guggenheim’s price target would indicate a potential upside of 66.23% from the company’s current price.

A number of other analysts also recently weighed in on MAZE. Leerink Partners initiated coverage on shares of Maze Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $28.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $30.00 price target on the stock.

Maze Therapeutics Trading Up 5.6 %

NASDAQ MAZE traded up $0.61 on Tuesday, reaching $11.43. The company had a trading volume of 30,132 shares, compared to its average volume of 338,307. Maze Therapeutics has a 52 week low of $10.66 and a 52 week high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.